![]() |
市場調查報告書
商品編碼
1375140
2028 年南美洲神經毒素市場預測 - COVID-19 影響和區域分析 - 按產品類型、應用和最終用戶South America Neurotoxins Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product Type, Application, and End User |
南美神經毒素市場預計將從2023年的2.8048億美元成長到2028年的5.2557億美元。預計2023年至2028年的年複合成長率為13.4%。
創新臉部美容產品的出現推動了南美洲神經毒素市場
預計神經毒素的整體市場將在預測期內呈指數級成長,以滿足日益成長的臉部美容需求。 2022年3月,Aquavit Pharmaceuticals, Inc.宣布提交「DTX-021」的研究新藥(IND),這是一種A型肉毒桿菌毒素,旨在治療中度至重度眉間紋。本產品是一種高度純化且經過臨床測試的可注射神經調節劑,含有源自肉毒桿菌產生的神經毒素的 900 kDa 蛋白質複合物。此外,Aquavit 正在透過推出 DTX-022 加速臨床試驗,其最終批准將被認為是首個、也是世界上第一個全臉部微注射神經毒素的產品。同樣,隨著減重趨勢的持續,胃肉毒桿菌已成為尋求非侵入性手術的患者的熱門選擇。它涉及使用內視鏡技術將肉毒桿菌注射到特定的胃部區域。透過這種技術,可以抑制胃部肌肉的收縮。由於這種限制,胃的排空過程需要更長的時間,這導致患者長時間感到飽腹感,導致食慾下降並改善與體重相關的健康問題/生活方式障礙,例如高血壓和糖尿病。因此,創新臉部美容產品的出現有助於南美洲神經毒素市場的成長。
南美洲神經毒素市場概況
南美洲神經毒素市場分為巴西、阿根廷、委內瑞拉和南美洲其他地區。該市場的成長主要是由於擴大採用微創和非侵入性美容手術、老年人接受度的提高、公眾對美容手術的認知不斷提高、技術先進且方便用戶使用的產品的可用性以及美容治療的需求不斷增加。由於最近的技術發展對巴西經濟產生了直接影響,並在很大程度上取得了進步,因此該區域市場可能會在預測期內得到推動。在巴西,採用具有廣泛適應症的微創和非侵入性美容手術(例如基於肉毒桿菌毒素的治療)是主要的市場驅動力。巴西 A 型肉毒桿菌素製劑的品牌名稱包括 Botox、Xeomin、Dysport、Botulift 和 Prosigne。此外,國際美容與整形外科醫生協會 (ISAPS) 2018 年報告顯示,基於肉毒桿菌毒素的治療是巴西最常見的非手術治療,佔非手術治療總數的 51%(約 392,530 例) 。節省成本的優勢和更高的工作效率被認為是製造業在南美洲建立基地的主要吸引力。
南美神經毒素市場收入及 2028 年預測(百萬美元)
南美洲神經毒素市場細分
南美神經毒素市場按產品類型、應用、最終用戶和國家細分。
根據產品類型,南美神經毒素市場細分為肉毒桿菌、dysport、xenomin 等。肉毒桿菌細分市場在 2023 年佔據最大的市場佔有率。
根據應用,南美神經毒素市場分為治療和美容市場。 2023 年,美容細分市場佔據更大的市場佔有率。
根據最終用戶,南美神經毒素市場分為醫院、專科診所、皮膚科診所等。 2023 年,醫院細分市場佔據最大市場佔有率。
根據國家/地區,南美洲神經毒素市場分為巴西、阿根廷、委內瑞拉和南美洲其他地區。 2023 年,巴西佔據市場佔有率主導地位。
AbbVie Inc、Hugel Inc、Ipsen SA、Meditox Inc 和 Merz Pharma GmbH & Co KGaA 是南美洲神經毒素市場的領先公司。
The South America neurotoxins market is expected to grow from US$ 280.48 million in 2023 to US$ 525.57 million by 2028. It is estimated to register a CAGR of 13.4% from 2023 to 2028.
Emergence of Innovative Facial Aesthetic Products Fuels South America Neurotoxins Market
The overall market for neurotoxins is expected to propel exponentially during the forecast period to meet the growing demand for facial aesthetics. In March 2022, Aquavit Pharmaceuticals, Inc. announced the submission of an Investigational New Drug (IND) of "DTX-021"-a botulinum toxin type A intended to treat moderate to severe glabellar lines. The product is a highly purified and clinically tested injectable neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. Also, Aquavit is accelerating clinical trials by introducing DTX-022, and its final approval will be recognized as the first-of-its-kind and the world's first pan-facial microinjection of neurotoxins. Likewise, with the ongoing weight loss trend, Gastric Botox has become a popular choice among patients seeking non-invasive procedures. It involves injecting Botox into specific stomach regions using an endoscopic technique. By this technique, the contraction of the stomach muscles is restrained. Due to the limitation, the stomach's evacuation process takes longer, which causes the patient to feel full for longer period, resulting in reduced appetite and improved weight-related health issues/lifestyle disorders such as high blood pressure and diabetes mellitus. Therefore, emergence of innovative facial aesthetic products helps the South America neurotoxin market to grow.
South America Neurotoxins Market Overview
The South America neurotoxin market is segmented into Brazil, Argentina, Venezuela, and the Rest of South America. Growth in this market is mainly driven by the growing adoption of minimally invasive and non-invasive aesthetic procedures, rising adoption among geriatric individuals, increasing public awareness about cosmetic procedures, availability of technologically advanced & user-friendly products, and increasing demand for aesthetic treatments. The regional market is likely to propel during the forecasted period owing to the recent technological developments that have made a direct impact on the economy of Brazil that has advanced to a large extent. In Brazil, the adoption of minimally invasive and non-invasive cosmetic procedures with a broad range of indications, such as botulinum-toxin-based treatment, are the major market drivers. The brand names of botulinum toxin A formulations available in Brazil involve Botox, Xeomin, Dysport, Botulift, and Prosigne. Additionally, the International Society of Aesthetics and Plastic Surgeons (ISAPS) 2018 report reveals that botulinum toxin-based treatment was the most common non-surgical procedure performed in Brazil, accounting for 51% (approx. 392,530) of the total non-surgical procedures. The cost savings advantage and higher work efficiencies achieved are cited as the major attracting points for manufacturing companies to establish bases in South America.
South America Neurotoxins Market Revenue and Forecast to 2028 (US$ Million)
South America Neurotoxins Market Segmentation
The South America neurotoxins market is segmented into product type, application, end user, and country.
Based on product type, the South America neurotoxins market is subsegmented into botox, dysport, xenomin, and others. The botox segment registered the largest market share in 2023.
Based on application, the South America neurotoxins market is segmented into therapeutic and aesthetic. The aesthetic segment held a larger market share in 2023.
Based on end user, the South America neurotoxins market is segmented into hospitals, specialty clinics, dermatology clinics, and others. The hospitals segment held the largest market share in 2023.
Based on country, the South America neurotoxins market is segmented into Brazil, Argentina, Venezuela, and the Rest of South America. Brazil dominated the market share in 2023.
AbbVie Inc, Hugel Inc, Ipsen SA, Medytox Inc, and Merz Pharma GmbH & Co KGaA are among the leading companies operating in the South America neurotoxins market.